Junovan has completed phase III trials involving 664 osteosarcoma patients IDM-Pharma has completed its first batch of Junovan.

It has been turned down by the FDA for use in Osteosarcoma

Company   IDM-Pharma

Information on IDM and Junovan

Overview

        1995 Biologic Therapy for Osteosarcoma using Liposome-Encapsulated Muramyl Tripeptide

In Vitro/Vivo

1991 Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro

1992 Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents

Aug. 1992 Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration

1993 Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma

 

          1989 Combined Muramyl-Encapsulated Tripeptide and Cisplatin in Dogs with Osteosarcoma

Dec. 1989 Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients

1990 Liposomal MTP-PE for the adjuvant therapy of osteosarcoma

Feb. 1991 Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma

April 1995 Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma

Mar. 2005 Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate